Anthem (ANTM) – Investment Analysts’ Recent Ratings Updates

Anthem (NYSE: ANTM) has recently received a number of price target changes and ratings updates:

  • 9/20/2017 – Anthem was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $207.00 price target on the stock. According to Zacks, “Anthem’s shares have outperformed the industry in last one year. The company’s diverse product portfolio has helped in improving underwriting results. Anthem’s strategic acquisitions, divestitures and ACO arrangements further pave the way for long-term growth. Its rising level of medical membership continues to boost the top line. Its strong capital position backs effective capital deployment. Its frequent share buyback programs and regular dividend payments primarily aim at enhancing shareholders’ value. The company has seen the Zacks Consensus Estimate for 2017 and 2018 earnings being revised upward over the last 60 days. Followed by strong results in first half of 2017, the company has raised the earnings and revenue guidance for 2017.”
  • 9/19/2017 – Anthem was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Anthem’s shares have outperformed the industry in last one year. The company’s diverse product portfolio has helped in improving underwriting results. Anthem’s strategic acquisitions, divestitures and ACO arrangements further pave the way for long-term growth. Its rising level of medical membership continues to boost the top line. Its strong capital position backs effective capital deployment. Its frequent share buyback programs and regular dividend payments primarily aim at enhancing shareholders’ value. The company has seen the Zacks Consensus Estimate for 2017 and 2018 earnings being revised upward over the last 60 days. Followed by strong results in first half of 2017, the company has raised the earnings and revenue guidance for 2017. However, the company's interest expenses increase due to mounting level of debt that continues to weigh on margins. Also softness in public exchange business remains a major headwind.”
  • 9/15/2017 – Anthem was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 9/14/2017 – Anthem had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $215.00 price target on the stock.
  • 9/14/2017 – Anthem was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $212.00 price target on the stock. According to Zacks, “Anthem’s shares have outperformed the industry in last one year. The company’s diverse product portfolio has helped in improving underwriting results. Anthem’s strategic acquisitions, divestitures and ACO arrangements further pave the way for long-term growth. Its rising level of medical membership continues to boost the top line. The company’s strong capital position backs effective capital deployment. Its frequent share buyback programs and regular dividend payments primarily aim at enhancing shareholders’ value. The company has seen the Zacks Consensus Estimate for 2017 and 2018 earnings being revised upward over the last 60 days. Followed by strong results in first half of 2017, the company has raised the earnings and revenue guidance for 2017.”
  • 9/12/2017 – Anthem was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Anthem’s shares have outperformed the industry in last one year. The company’s diverse product portfolio has helped in improving underwriting results. Anthem’s strategic acquisitions, divestitures and ACO arrangements further pave the way for long-term growth. Its rising level of medical membership continues to boost the top line. The company’s strong capital position backs effective capital deployment. Its frequent share buyback programs and regular dividend payments primarily aim at enhancing shareholders’ value. The company has seen the Zacks Consensus Estimate for 2017 and 2018 earnings being revised upward over the last 60 days. Followed by strong results in first half of 2017, the company has raised the earnings and revenue guidance for 2017. However, weak public exchange business remains a major area of concern. Also, rising level of debt continues to weigh on margins.”
  • 9/6/2017 – Anthem was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $221.00 price target on the stock. According to Zacks, “Anthem’s shares have outperformed the industry in last one year. The company’s diverse product portfolio has helped in improving underwriting results. Anthem’s strategic acquisitions, divestitures and ACO arrangements further pave the way for long-term growth. Its rising level of medical membership continues to boost the top line. The company’s strong capital position backs effective capital deployment. Its frequent share buyback programs and regular dividend payments primarily aim at enhancing shareholders’ value. The stock has seen the Zacks Consensus Estimate for 2017 and 2018 earnings being revised upward over the last 60 days. Followed by strong results in first half of 2017, the company has raised the earnings and revenue guidance for 2017.”
  • 9/6/2017 – Anthem was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 9/5/2017 – Anthem was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Anthem’s shares have outperformed the industry in last one year. The company’s diverse product portfolio has helped in improving underwriting results. Anthem’s strategic acquisitions, divestures and ACO arrangements further pave the way for long-term growth. Its rising level of medical membership continues to boost the top line. The company’s strong capital position backs effective capital deployment. Its frequent share buyback programs and regular dividend payments primarily aim at enhancing shareholders’ value. The stock has seen the Zacks Consensus Estimate for 2017 and 2018 earnings being revised upward over the last 60 days. Followed by strong results in first half of 2017, the company has raised the earnings and revenue guidance for 2017. However, the company’s rising level of debt results in increasing interest expenses that continues to drain the margin. Also its weak public exchange business bothers.”
  • 8/30/2017 – Anthem was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Anthem’s shares have outperformed the industry in last one year. The company’s diverse product portfolio has helped in improving underwriting results. Anthem’s strategic acquisitions, divestures and ACO arrangements further pave the way for long-term growth. Its rising level of medical membership continues to boost the top line. The company’s strong capital position backs effective capital deployment. Its frequent share buyback programs and regular dividend payments primarily aim at enhancing shareholders’ value. In last 30 days, the Zacks Consensus Estimate for 2017 and 2018 has been revised upward. Followed by strong results in first half of 2017, the company has raised the earnings and revenue guidance for 2017. However, the company’s high-debt level poses financial risk. Rising interest expenses may hurt margins.  Also, the company’s weak public exchange business continues to bother.”
  • 8/24/2017 – Anthem was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $219.00 price target on the stock. According to Zacks, “Anthem’s shares have outperformed the industry in last one year. The company’s diverse product portfolio has helped in improving underwriting results. Anthem’s strategic acquisitions, divestures and ACO arrangements further pave the way for long-term growth. The company’s strong capital position backs effective capital deployment. The company’s frequent share buyback programs and regular dividend payments primarily aim at enhancing shareholders’ value. In last 30 days, the Zacks Consensus Estimate for 2017 and 2018 has revised upward. Followed by strong results in first half of 2017, the company has raised the earnings and revenue guidance for 2017. However, the company’s high-debt level poses financial risk. Rising interest expenses may hurt margins.  Also, the company’s weak public exchange business continues to bother.”
  • 8/23/2017 – Anthem was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Anthem’s shares have outperformed the industry in last one year. Tthe company’s diverse product portfoliohas  helped in improving underwriting results. Anthem’s strategic acquisitions, divestures and ACO arrangements further paves the way for long-term growth. The company’s strong capital position backs effective capital deployment. Frequent share buybacks and regular dividend payments primarily aim at enhancing shareholders’ value. During the most recently reported quarter its earnings per share not only surpassed the Zacks Consensus Estimate but also rose year over year on higher revenues. However rising interest expenses associated to its high-debt levels and weak public exchange business bothers.”
  • 8/20/2017 – Anthem had its “hold” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $204.00 price target on the stock.
  • 8/17/2017 – Anthem had its price target raised by analysts at Morgan Stanley from $196.00 to $201.00. They now have an “equal weight” rating on the stock.
  • 7/31/2017 – Anthem was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 7/26/2017 – Anthem had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $215.00 price target on the stock, up previously from $210.00. They wrote, “This morning, Anthem reported 2Q17 results. Revenue was essentially in line with expectations while adjusted EPS of $3.37 compares to our estimate of $2.90 and FactSet consensus of $3.24.””

Anthem, Inc. (NYSE ANTM) traded up 1.13% on Wednesday, reaching $183.49. The company had a trading volume of 2,204,564 shares. The firm has a market capitalization of $48.18 billion, a P/E ratio of 17.35 and a beta of 0.70. The company’s 50-day moving average price is $191.59 and its 200 day moving average price is $182.25. Anthem, Inc. has a 1-year low of $114.85 and a 1-year high of $198.98.

Anthem (NYSE:ANTM) last released its quarterly earnings results on Wednesday, July 26th. The company reported $3.37 earnings per share for the quarter, topping the consensus estimate of $3.23 by $0.14. Anthem had a net margin of 3.24% and a return on equity of 12.93%. The firm had revenue of $22.20 billion during the quarter, compared to the consensus estimate of $22.25 billion. During the same quarter in the prior year, the firm earned $3.33 EPS. The company’s revenue for the quarter was up 4.3% on a year-over-year basis. On average, equities analysts forecast that Anthem, Inc. will post $11.83 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Monday, September 25th. Investors of record on Friday, September 8th will be given a dividend of $0.70 per share. This represents a $2.80 annualized dividend and a dividend yield of 1.53%. The ex-dividend date of this dividend is Thursday, September 7th. This is an increase from Anthem’s previous quarterly dividend of $0.65. Anthem’s dividend payout ratio is 26.52%.

In related news, Director Julie A. Hill sold 524 shares of the company’s stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $190.80, for a total transaction of $99,979.20. Following the completion of the sale, the director now owns 36,924 shares of the company’s stock, valued at approximately $7,045,099.20. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Joseph Swedish sold 21,125 shares of the company’s stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $197.00, for a total transaction of $4,161,625.00. Following the sale, the insider now directly owns 87,668 shares of the company’s stock, valued at approximately $17,270,596. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 30,776 shares of company stock valued at $6,007,143. Insiders own 0.36% of the company’s stock.

Anthem, Inc is a health benefits company. The Company operates through three segments: Commercial and Specialty Business, Government Business and Other. It offers a spectrum of network-based managed care plans to large and small employer, individual, Medicaid and Medicare markets. Its managed care plans include preferred provider organizations; health maintenance organizations; point-of-service plans; indemnity plans and other hybrid plans, including consumer-driven health plans; and hospital only and limited benefit products.

Receive News & Ratings for Anthem Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthem Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply